title: Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?
abstract: Current guidelines do not recommend the routine use of somatostatin analogue pretreatment prior to surgery in patients with growth hormone-secreting pituitary tumours. In theory, presurgical use of somatostatin analogues should improve metabolic control and reduce soft tissue swelling, leading to improved anaesthetic outcomes. Shrinkage of tumours prior to surgery might also improve surgical remission rates. Hence, this article addresses the question: Should all patients with acromegaly receive a somatostatin analogue prior to surgery? Clinical trials published before December 2013 were reviewed, although literature in this area remains relatively deficient. We conclude: (i) On the basis of limited data available, somatostatin analogue pretreatment does not improve anaesthetic or immediate postoperative outcomes (i.e. hospital stay, rates of surgical complications and postoperative pituitary dysfunction). (ii) Somatostatin analogues should be considered in all patients with growth hormone-secreting macroadenomas, including invasive macroadenomas, when the overall surgical remission rate for macroadenomas at the treating centre is below 50%. Four recent RCTs have demonstrated increased rates of surgical remission using such an approach. (iii) When deemed appropriate, patients should be treated with somatostatin analogues for at least 3 months before surgery; there is currently no evidence that treatment beyond 6 months provides any additional benefit. Patients with minimally invasive macroadenomas are those most likely to benefit in terms of improved surgical remission.
authors.affiliation: The JJR Macleod Centre for Diabetes, Endocrinology & Metabolism (Mac-DEM), David Anderson Building, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.
authors.forename: Jubbin J
authors.initials: JJ
authors.lastname: Jacob
authors.forename: John S
authors.initials: JS
authors.lastname: Bevan
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000601:surgery; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control; D007442:Intubation, Intratracheal / Q000009:adverse effects; D020360:Neoadjuvant Therapy / Q000379:methods*; D015282:Octreotide / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011300:Preoperative Care; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide